ResearchMoz

Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) potentially supplemented by approvals for Alzheimers disease

GBI Research
Published Date » 2013-05-03
No. Of Pages » N/A
   
 GBI Research’s report: Immunoglobulin Market to 2019 provides in-depth analysis of the global immunoglobulin market. The report analyzes the markets for immunoglobulin products in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan. The revenue and annual cost of therapy are forecast for the key geographies and in seven key therapeutic segments, along with epidemiology data, until 2019.  
   
 The seven key therapeutic segments are Primary Immunodeficiency (PI), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), Guillain-Barré Syndrome (GBS), Myasthenia Gravis (MG), Idiopathic Thrombocytopenic Purpura (ITP), and Chronic Lymphocytic Leukemia (CLL). The report also profiles the...
Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Immunoglobulins Market to 2019 - Introduction
2.1 Overview

3 Immunoglobulins Market to 2019 - Market Overview
3.1 Revenue
3.2 Annual Cost of Therapy
3.3 Immunoglobulins Market Drivers and Restraints
3.3.1 Market Drivers
3.3.2 Restraints

4 Immunoglobulins Market to 2019 - Geographical Landscape
4.1 US
4.1.1 Revenue
4.1.2 Annual Cost of Therapy
4.2 Top Five European Countries
4.2.1 Revenue
4.2.2 Annual Cost of Therapy
4.3 Japan
4.3.1 Revenue
4.3.2 Annual Cost of Therapy

5 Immunoglobulins Market to 2019 - Therapeutic Landscape
5.1 Main Therapeutic Indications
5.1.1 Indicated Conditions for Intravenous Immunoglobulin Usage - US
5.1.2 Indications for Intravenous Immunoglobulin Usage - Europe
5.1.3 Guidelines for Intravenous Immunoglobulin Usage - UK
5.1.4 Indications for Intravenous Immunoglobulin Usage - Japan
5.2 Revenue Share for the Major Therapeutic Indications
5.3 Primary Immunodeficiency Market
5.3.1 Introduction
5.3.2 Revenue
5.3.3 Annual Cost of Therapy
5.3.4 Epidemiology
5.3.5 Current Use
5.3.6 Geographical Segmentation
5.4 Guillain-Barré Syndrome Market
5.4.1 Introduction
5.4.2 Revenue
5.4.3 Annual Cost of Therapy
5.4.4 Epidemiology
5.4.5 Current Use for Therapies
5.4.6 Geographical Segmentation
5.5 Chronic Lymphocytic Leukemia Market
5.5.1 Introduction
5.5.2 Revenue
5.5.3 Annual Cost of Therapy
5.5.4 Epidemiology
5.5.5 Current Use
5.5.6 Geographical Segmentation
5.6 Chronic Inflammatory Demyelinating Polyneuropathy Market
5.6.1 Introduction
5.6.2 Revenue
5.6.3 Annual Cost of Therapy
5.6.4 Epidemiology
5.6.5 Current Use
5.6.6 Geographical Segmentation
5.7 Myasthenia Gravis Market
5.7.1 Introduction
5.7.2 Revenue
5.7.3 Annual Cost of Therapy
5.7.4 Epidemiology
5.7.5 Current Use
5.7.6 Geographical Segmentation
5.8 Multifocal Motor Neuropathy Market
5.8.1 Introduction
5.8.2 Revenue
5.8.3 Annual Cost of Therapy
5.8.4 Epidemiology
5.8.5 Current Use
5.8.6 Geographical Segmentation
5.9 Idiopathic Thrombocytopenic Purpura
5.9.1 Introduction
5.9.2 Revenue
5.9.3 Annual Cost of Therapy
5.9.4 Epidemiology
5.9.5 Current Use
5.9.6 Geographical Segmentation

6 Immunoglobulins Market to 2019 - Profiles of Marketed Products
6.1 Overview
6.2 Privigen
6.2.1 Overview
6.2.2 Approved Indications
6.2.3 Safety
6.2.4 Efficacy
6.3 Gammagard S/D
6.3.1 Overview
6.3.2 Approved Indications
6.3.3 Safety
6.3.4 Efficacy
6.4 Gammagard Liquid
6.4.1 Overview
6.4.2 Approved Indications
6.4.3 Safety
6.4.4 Efficacy
6.5 Octagam 5%
6.5.1 Overview
6.5.2 Approved Indications
6.5.3 Safety
6.5.4 Efficacy
6.6 Flebogamma 10% DIF
6.6.1 Overview
6.6.2 Approved Indications
6.6.3 Safety
6.6.4 Efficacy
6.7 Gamunex-C
6.7.1 Overview
6.7.2 Approved Indications
6.7.3 Safety
6.7.4 Efficacy
6.8 Gammaplex
6.8.1 Overview
6.8.2 Approved Indications
6.8.3 Safety
6.8.4 Efficacy
6.9 HyQvia
6.9.1 Overview
6.9.2 Approved Indications
6.9.3 Safety
6.9.4 Efficacy
6.10 Bivigam
6.10.1 Overview
6.10.2 Approved Indications
6.10.3 Safety
6.10.4 Efficacy

7 Immunoglobulins Market to 2019 - Pipeline Analysis
7.1 Research and Development Pipeline
7.2 Major Pipeline Product Profiles
7.2.1 IVIG3I Grifols 10%
7.2.2 RI-002 (IVIG)

8 Immunoglobulins Market to 2019 - Competitive Landscape
8.1 Baxter International Inc.
8.1.1 Business Description
8.1.2 Recent Developments
8.2 Biotest Pharmaceuticals
8.2.1 Business Description
8.2.2 Recent Developments
8.3 Bio Products Laboratory Ltd.
8.3.1 Business Description
8.3.2 Recent Developments
8.4 CSL Behring Limited
8.4.1 Business Description
8.4.2 Recent Developments
8.5 Grifols S.A.
8.5.1 Business Description
8.5.2 Recent Developments
8.6 Octapharma AG
8.6.1 Business Description
8.6.2 Recent Developments

9 Immunoglobulins Market to 2019 - M&A and Licensing Deals Landscape
9.1 M&A Deals
9.1.1 Grifols Buys 60% of Progenika Biopharma
9.1.2 Grifols Acquires 40% of the Capital of Biotechnology Firm VCN Bioscience
9.1.3 Grifols Purchases Three Plasma Donation Centers in the US from Canada’s Cangene
9.1.4 Baxter Enhances Renal Therapies Portfolio with Acquisition of Gambro
9.2 R&D Licensing Agreements
9.2.1 Baxter and Onconova Announce European Licensing Agreement for Anti-Cancer Compound Rigosertib
9.2.2 Baxter Announces Collaboration with Sanquin to Expand Capacity for Plasma Therapies
9.2.3 Baxter Announces 20 Year Partnership with Hemobras in Brazil

10 Immunoglobulins Market to 2019 - Asia-Pacific and China
10.1 India
10.1.1 Overview
10.1.2 Regulatory Landscape
10.1.3 National Institute for Biologicals
10.1.4 Marketed Products
10.1.5 Product Profiles
10.1.6 Company Profiling
10.2 China
10.2.1 Overview
10.2.2 Regulatory Information
10.2.3 Marketed Products
10.2.4 Company Profiling
10.3 Australia
10.3.1 Overview
10.3.2 Regulatory Landscape
10.3.3 Marketed Products
10.3.4 Product Profiles
10.3.5 Company Profiling

11 Global Immunoglobulins Market: Appendix
11.1 Market Definitions
11.2 Abbreviations
11.3 References
11.4 Research Methodology
11.4.1 Coverage
11.4.2 Secondary Research
11.4.3 Primary Research
11.4.4 Expert Panel Validation
11.5 Contact Us
11.6 Disclaimer

List of Tables


Table 1: Immunoglobulins Market, Top Seven Markets, Revenue ($bn), 2006-2012
Table 2: Immunoglobulins Market, Top Seven Markets, Revenue Forecast ($bn), 2012-2019
Table 3: Immunoglobulins Market, Top Seven Markets, Annual Cost of Therapy ($), 2006-2012
Table 4: Immunoglobulins Market, Top Seven Markets, Annual Cost of Therapy Forecast ($), 2012-2019
Table 5: Immunoglobulins Market, US, Revenue ($bn), 2006-2012
Table 6: Immunoglobulins Market, US, Revenue Forecast ($bn), 2012-2019
Table 7: Immunoglobulins Market, US, Annual Cost of Therapy ($), 2006-2012
Table 8: Immunoglobulins Market, US, Annual Cost of Therapy Forecast ($), 2012-2019
Table 9: Immunoglobulins Market, Top Five European Countries, Revenue ($m), 2006-2012
Table 10: Immunoglobulins Market, Top Five European Countries, Revenue Forecast ($m), 2012-2019
Table 11: Immunoglobulins Market, Top Five European Countries, Annual Cost of Therapy ($), 2006-2012
Table 12: Immunoglobulins Market, Top Five European Countries, Annual Cost of Therapy Forecast ($), 2012-2019
Table 13: Immunoglobulins Market, Japan, Revenue ($m), 2006-2012
Table 14: Immunoglobulins Market, Japan, Revenue Forecast ($m), 2012-2019
Table 15: Immunoglobulins Market, Japan, Annual Cost of Therapy ($), 2006-2012
Table 16: Immunoglobulins Market, Japan, Annual Cost of Therapy Forecast ($), 2012-2019
Table 17: Immunoglobulins Market, US, Approved Indications for IVIG Usage, 2012
Table 18: Immunoglobulins Market, EU, Indicated Conditions for IVIG Usage, 2012
Table 19: Immunoglobulins Market, UK, Guidelines for IVIG Usage, 2012
Table 20: Immunoglobulins Market, Top Seven Markets, PI, Revenue ($bn), 2006-2012
Table 21: Immunoglobulins Market, Top Seven Markets, PI, Revenue Forecast ($bn), 2012-2019
Table 22: Immunoglobulins Market, Top Seven Markets, PI, Annual Cost of Therapy ($), 2006-2012
Table 23: Immunoglobulins Market, Top Seven Markets, PI, Annual Cost of Therapy Forecast ($),
2012-2019
Table 24: Immunoglobulins Market, Top Seven Markets, PI, Epidemiology, 2006-2012
Table 25: Immunoglobulins Market, Top Seven Markets, PI, Epidemiology Forecast, 2012-2019
Table 26: Immunoglobulins Market, Top Seven Markets, PI, Geographical Revenue ($m), 2006-2012
Table 27: Immunoglobulins Market, Top Seven Markets, PI, Geographical Revenue Forecast ($m),
2012-2019
Table 28: Immunoglobulins Market, Top Seven Markets, GBS, Revenue ($m), 2006-2012
Table 29: Immunoglobulins Market, Top Seven Markets, GBS, Revenue Forecast ($m), 2012-2019
Table 30: Immunoglobulins Market, Top Seven Markets, GBS, Annual Cost of Therapy ($), 2006-2012
Table 31: Immunoglobulins Market, Top Seven Markets, GBS, Annual Cost of Therapy Forecast ($),
2012-2019
Table 32: Immunoglobulins Market, Top Seven Markets, GBS, Epidemiology, 2006-2012
Table 33: Immunoglobulins Market, Top Seven Markets, GBS, Epidemiology Forecast, 2012-2019
Table 34: Immunoglobulins Market, Top Seven Markets, GBS, Geographical Revenue ($m), 2006-2012
Table 35: Immunoglobulins Market, Top Seven Markets, GBS, Geographical Revenue Forecast ($m),
2012-2019
Table 36: Immunoglobulins Market, Top Seven Markets, CLL, Revenue ($m), 2006-2012
Table 37: Immunoglobulins Market, Top Seven Markets, CLL, Revenue Forecast ($m), 2012-2019
Table 38: Immunoglobulins Market, Top Seven Markets, CLL, Annual Cost of Therapy ($), 2006-2012
Table 39: Immunoglobulins Market, Top Seven Markets, CLL, Annual Cost of Therapy Forecast ($),
2012-2019
Table 40: Immunoglobulins Market, Top Seven Markets, CLL, Epidemiology, 2006-2012
Table 41: Immunoglobulins Market, Top Seven Markets, CLL, Epidemiology Forecast, 2012-2019
Table 42: Immunoglobulins Market, Top Seven Markets, CLL, Geographical Revenue ($m), 2006-2012
Table 43: Immunoglobulins Market, Top Seven Markets, CLL, Geographical Revenue Forecast ($m),
2012-2019
Table 44: Immunoglobulins Market, Top Seven Markets, CIDP, Revenue ($m), 2006-2012
Table 45: Immunoglobulins Market, Top Seven Markets, CIDP, Revenue Forecast ($m), 2012-2019
Table 46: Immunoglobulins Market, Top Seven Markets, CIDP, Annual Cost of Therapy ($), 2006-2012
Table 47: Immunoglobulins Market, Top Seven Markets, CIDP, Annual Cost of Therapy Forecast ($),
2012-2019
Table 48: Immunoglobulins Market, Top Seven Markets, CIDP, Epidemiology, 2006-2012
Table 49: Immunoglobulins Market, Top Seven Markets, CIDP, Epidemiology Forecast, 2012-2019
Table 50: Immunoglobulins Market, Top Seven Markets, CIDP, Geographical Revenue ($m), 2006-2012
Table 51: Immunoglobulins Market, Top Seven Markets, CIDP, Geographical Revenue Forecast ($m),
2012-2019
Table 52: Immunoglobulins Market, Top Seven Markets, MG, Revenue ($m), 2006-2012
Table 53: Immunoglobulins Market, Top Seven Markets, MG, Revenue Forecast ($m), 2012-2019
Table 54: Immunoglobulins Market, Top Seven Markets, MG, Annual Cost of Therapy ($), 2006-2012
Table 55: Immunoglobulins Market, Top Seven Markets, MG, Annual Cost of Therapy Forecast ($),
2012-2019
Table 56: Immunoglobulins Market, Top Seven Markets, MG, Epidemiology, 2006-2012
Table 57: Immunoglobulins Market, Top Seven Markets, MG, Epidemiology Forecast, 2012-2019
Table 58: Immunoglobulins Market, Top Seven Markets, MG, Geographical Revenue ($m), 2006-2012
Table 59: Immunoglobulins Market, Top Seven Markets, MG, Geographical Revenue Forecast ($m),
2012-2019
Table 60: Immunoglobulins Market, Top Seven Markets, MMN, Revenue ($m), 2006-2012
Table 61: Immunoglobulins Market, Top Seven Markets, MMN, Revenue Forecast ($m), 2012-2019
Table 62: Immunoglobulins Market, Top Seven Markets, MMN, Annual Cost of Therapy ($), 2006-2012
Table 63: Immunoglobulins Market, Top Seven Markets, MMN, Annual Cost of Therapy Forecast ($),
2012-2019
Table 64: Immunoglobulins Market, Top Seven Markets, MMN, Epidemiology, 2006-2012
Table 65: Immunoglobulins Market, Top Seven Markets, MMN, Epidemiology Forecast, 2012-2019
Table 66: Immunoglobulins Market, Top Seven Markets, MMN, Geographical Revenue ($m), 2006-2012
Table 67: Immunoglobulins Market, Top Seven Markets, MMN, Geographical Revenue Forecast ($m), 2012-2019
Table 68: Immunoglobulins Market, Top Seven Markets, ITP, Revenue ($m), 2006-2012
Table 69: Immunoglobulins Market, Top Seven Markets, ITP, Revenue Forecast ($m), 2012-2019
Table 70: Immunoglobulins Market, Top Seven Markets, ITP, Annual Cost of Therapy ($), 2006-2012
Table 71: Immunoglobulins Market, Top Seven Markets, ITP, Annual of Cost Therapy Forecast ($),
2012-2019
Table 72: Immunoglobulins Market, Top Seven Markets, ITP, Epidemiology, 2006-2012
Table 73: Immunoglobulins Market, Top Seven Markets, ITP, Epidemiology Forecast, 2012-2019
Table 74: Immunoglobulins Market, Top Seven Markets, ITP, Geographical Revenue ($m), 2006-2012
Table 75: Immunoglobulins Market, Top Seven Markets, ITP, Geographical Revenue Forecast ($m),
2012-2019
Table 76: Immunoglobulins Market, US, FDA-Approved IVIG Products by Therapeutic Indication,
1994-2013
Table 77: Immunoglobulins Market, Top Five European Countries, EMA-Approved IVIG Products by Therapeutic Indication, 2004-2013
Table 78: Immunoglobulins Market, Global, Phase III Pipeline Molecules, 2013
Table 79: Immunoglobulins Market, Global, Alzheimer’s Disease, Pipeline Molecules, 2013
Table 80: Immunoglobulins Market, Grifols, Global, Marketed Immunoglobulin Products, 2013
Table 81: Immunoglobulins Market, India, PI, Marketed Products, 2013
Table 82: Immunoglobulins Market, India, GBS, Marketed Products, 2013
Table 83: Immunoglobulins Market, India, CLL, Marketed Products, 2013
Table 84: Immunoglobulins Market, India, CIDP, Marketed Products, 2013
Table 85: Immunoglobulins Market, India, ITP, Marketed Products, 2013
Table 86: Immunoglobulins Market, India, Reliance Life Sciences, Key Pipeline Products, 2012-2013
Table 87: Immunoglobulins Market, India, Zydus Cadila, Key Marketed Products, 2012-2013
Table 88: Immunoglobulins Market, India, Sun Pharmaceuticals, Generic Versions of Key Marketed Products, 2012-2013
Table 89: Immunoglobulins Market, China, Blood and Blood Products Industry, 1985-2012
Table 90: Immunoglobulins Market, Australia, IVIG Issued to Patients, by Therapeutic Indication, 2011
Table 91: Immunoglobulins Market, Australia, Marketed Products, CIDP, 2013
Table 92: Immunoglobulins Market, Australia, Marketed Products, CLL, 2013
Table 93: Immunoglobulins Market, Australia, Marketed Products, GBS, 2013
Table 94: Immunoglobulins Market, Australia, Marketed Products, ITP, 2013
Table 95: Immunoglobulins Market, Australia, Marketed Products, PI, 2013

List of Figures


Figure 1: Immunoglobulins Market, Top Seven Markets, Revenue Forecast ($bn), 2006-2019
Figure 2: Immunoglobulins Market, Top Seven Markets, Annual Cost of Therapy Forecast ($), 2006-2019
Figure 3: Immunoglobulins Market, US, Revenue Forecast ($bn), 2006-2019
Figure 4: Immunoglobulins Market, US, Annual Cost of Therapy Forecast ($), 2006-2019
Figure 5: Immunoglobulins Market, Top Five European Countries, Revenue Forecast ($m), 2006-2019
Figure 6: Immunoglobulins Market, Top Five European Countries, Annual Cost of Therapy ($), 2006-2019
Figure 7: Immunoglobulins Market, Japan, Revenue Forecast ($m), 2006-2019
Figure 8: Immunoglobulins Market, Japan, Annual Cost of Therapy ($), 2006-2019
Figure 9: Immunoglobulins Market, Top Seven Markets, Market Share by Therapeutic Indication (%), 2012
Figure 10: Immunoglobulins Market, Top Seven Markets, PI, Revenue Forecast ($bn), 2006-2019
Figure 11: Immunoglobulins Market, Top Seven Markets, PI, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 12: Immunoglobulins Market, Top Seven Markets, PI, Geographical Revenue Forecast ($m),
2006-2019
Figure 13: Immunoglobulins Market, Top Seven Markets, GBS, Revenue Forecast ($m), 2006-2019
Figure 14: Immunoglobulins Market, Top Seven Markets, GBS, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 15: Immunoglobulins Market, Top Seven Markets, GBS, Geographical Revenue Forecast ($m),
2006-2019
Figure 16: Immunoglobulins Market, Top Seven Markets, CLL, Revenue Forecast ($m), 2006-2019
Figure 17: Immunoglobulins Market, Top Seven Markets, CLL, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 18: Immunoglobulins Market, Top Seven Markets, CLL, Geographical Revenue Forecast ($m),
2006-2019
Figure 19: Immunoglobulins Market, Top Seven Markets, CIDP, Revenue Forecast ($m), 2006-2019
Figure 20: Immunoglobulins Market, Top Seven Markets, CIDP, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 21: Immunoglobulins Market, Top Seven Markets, CIDP, Geographical Revenue Forecast ($m),
2006-2019
Figure 22: Immunoglobulins Market, Top Seven Markets, MG, Revenue Forecast ($m), 2006-2019
Figure 23: Immunoglobulins Market, Top Seven Markets, MG, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 24: Immunoglobulins Market, Top Seven Markets, MG, Geographical Revenue Forecast ($m),
2006-2019
Figure 25: Immunoglobulins Market, Top Seven Markets, MMN, Revenue Forecast ($m), 2006-2019
Figure 26: Immunoglobulins Market, Top Seven Markets, MMN, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 27: Immunoglobulins Market, Top Seven Markets, MMN, Geographical Revenue Forecast ($m), 2006-2019
Figure 28: Immunoglobulins Market, Top Seven Markets, ITP, Revenue Forecast ($m), 2006-2019
Figure 29: Immunoglobulins Market, Top Seven Markets, ITP, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 30: Immunoglobulins Market, Top Seven Markets, ITP, Geographical Revenue Forecast ($m),
2006-2019
Figure 31: Immunoglobulins Market, US, FDA-Approved Products by Therapeutic Indication, 2003-2013
Figure 32: Immunoglobulins Market, Australia, IVIG Issued (g/1,000 population), 2006-2012
Figure 33: Immunoglobulins Market, Australia, IVIG Issued to Patients, by Therapeutic Indication, 2011

Upcoming Reports:

Electroactive Polymers Market - Global Industry Analysis, Size, Growth, Share, And Forecast, 2012 - 2018
By - Transparency Market Research
Polymers exhibiting change in their size and shape in the presence of an electric field are referred to as electroactive polymers. They are most commonly used in sensors and actuators, as they can withstand large force. Conductive plastics emerged as the leading type of electroactive polymer which accounted for approximately 84.2% of the total electroactive market revenue in 2011.  North America was the biggest market for electroactive polymers followed by Europe and Asia Pacific. Some of the major factors driving the global market for electroactive polymers include...
Fat Replacers And Salt Reducers Market - Global Industry Analysis, Market Size, Share, Growth, Trends And Forecast, 2012 - 2018
By - Transparency Market Research
Fat replacers are used in the food and beverages industry. They are substances that are used as fat substitutes in food items. They are primarily used for reducing the calorie content in food and yet provide the same taste and texture. Some of the types of fat replacers are carbohydrate based fat replacers, fat based fat replacers and protein based fat replacers.  The global market for fat replacers and salt reducers is expected to grow at a healthy rate for the next five years. North America is the biggest market for fat replacers.  The key factors driving the...
Spectacles Market - Global Industry Size, Market Share, Trends, Analysis And Forecasts 2012 - 2018
By - Transparency Market Research
Global spectacles market is forecasted to grow at the compounded annual growth rate of 3% and reach the market value of $24 billion by the year 2016. This growth is mainly driven by increasing number of population suffering from refractive errors and rising awareness and cost effectiveness of eye care devices over refractive surgeries. About one third of population aging more than 40 years suffers from refractive errors in US and Western Europe. Occurrence of myopia is higher, around 70-90% in some Asian countries. Compared to men, females are at higher risk of developing...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

High-sodium Diet Increases Risks of Cardiovascular Diseases in Type 2 Diabetics
Jul 24, 2014  
A new research has found relation between the amount of salt in diet of diabetics and their chances of suffering from cardiovascular diseases. The research has stated that diabetics who have a high-salt diet are on a higher risk of having a chronic heart disease as compared to the ones who eat less salt.  The study’s findings provide evidences that support the benefits of a...
Strides Arcolab Bags USFDA Approval for Transplant Drug
Jul 24, 2014  
Indian pharmaceutical company Strides Arcolab has received the approval of the USFDA to sell its transplant drug Tacrolimus in the US market. The capsule is an immune-suppressant that is used for preventing organ rejection that may occur in transplant surgeries of organs such as kidneys, heart or liver in some patients.  USFDA has allowed the sale of the tablets in 5 mg, 1 mg and 0.5...
Chinese manufacturing gauge gets a hike after months
Jul 24, 2014  
China manufacturing gauge has climbed to its 18-month high this month, which has boosted the government’s chance of meeting the target for economic growth set for 2014, by a percentage of 7.5. The Purchasing Managers Index (PMI) preliminary from Markit Economics and HSBC Holdings Plc was at 52.0 and its has topped the 51.0 median estimate. These numbers indicate an above 50 mark. The...
Paracetamol doesn’t speed recovery or reduce low back pain: Study
Jul 24, 2014  
Paracetamol, which has long since been prescribed as a painkiller for severe low back pain, is no better than placebo; findings of a recent study in Australia have shown. The trial that was published on Thursday found that the universally recommended painkiller neither speeds recovery nor reduces the pain. Paracetamol is merely acts as a placebo or dummy pills doing nothing to ease the...
Early Treatment to Cure HIV virus Might not be Effective
Jul 23, 2014  
According to a research study, the virus of AIDS, HIV has the capacity of creating invulnerable strongholds in the host’s body rapidly. This has dashed hopes of early treatment for the condition, which might have been helpful to cure the virus. In one case, a baby was thought to be cured with the new treatment after its birth, however, the virus emerged couple of years later. A...